The present identification of a cardioprotective loss-of-function polymorphism of the human P2RY4 gene correlated with reduced plasma levels of fasting glucose and NT-proBNP in CAD patients, as well as the insulin sensitivity in P2Y4-deficient mice, support the notion that this nucleotide receptor constitutes another candidate for the development of such antagonists. This evidence concerns the gene INS and coronary artery disorder.